ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors

Kasun, Wanigasooriya; Robert, Tyler; Joao D., Barros-Silva; Yashashwi, Sinha; Tariq, Ismail; Andrew D., Beggs
Cancers2020-5-18DOI: 10.3390/cancers12051278
7被引6阅读
引用收藏
分享

摘要

<jats:p>Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting targets along this pathway, in enhancing radiotherapy response. We identified several studies using in vitro cancer cell lines, in vivo tumour xenografts and a few Phase I/II clinical trials. Most of the current evidence in this area comes from glioblastoma multiforme, non-small cell lung cancer, head and neck cancer, colorectal cancer, and prostate cancer. The biological basis for radiosensitivity following pathway inhibition was through inhibited DNA double strand break repair, inhibited cell proliferation, enhanced apoptosis and autophagy as well as tumour microenvironment changes. Dual PI3K/mTOR inhibition consistently demonstrated radiosensitisation of all types of cancer cells. Single pathway component inhibitors and other inhibitor combinations yielded variable outcomes especially within early clinical trials. There is ample evidence from preclinical studies to suggest that direct pharmacological inhibition of the PI3K/AKT/mTOR pathway components can radiosensitise different types of cancer cells. We recommend that future in vitro and in vivo research in this field should focus on dual PI3K/mTOR inhibitors. Early clinical trials are needed to assess the feasibility and efficacy of these dual inhibitors in combination with radiotherapy in brain, lung, head and neck, breast, prostate and rectal cancer patients.</jats:p>

相关
加载中…
  • The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy
    Du, Jie; Chen, Fuqiang; Yu, Jiahua; Jiang, Lijun; Zhou, Meijuan*Molecular Cancer Research, 2021, 19(11): 1889-1899.被引 8
  • Ginsenoside Rg3 enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/AKT signaling pathway
    Li, Jialin; Yang, Bo*In Vitro Cellular and Developmental Biology - Animal, 2023.
  • Targeting DNA repair in combination with radiotherapy in pancreatic cancer: a systematic review of preclinical studies
    Waisse Waissi; Adrien Paix; Anaïs Nicol; Georges Noël; Hélène BurckelCritical Reviews in Oncology/Hematology, 2020, 103060.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancers
发表日期
2020-05-18
卷期
第 12 卷, 第 5 期
页码
1278
DOI
10.3390/cancers12051278
期刊收录
NSL.SCIE
期刊等级
3区

作者

  • K

    Kasun, Wanigasooriya (第一作者)

  • R

    Robert, Tyler

查看全部 6 位作者收起作者
  • J

    Joao D., Barros-Silva

  • Y

    Yashashwi, Sinha

  • T

    Tariq, Ismail

  • A

    Andrew D., Beggs

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417